Galectin-3 plasmapheresis therapy
The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.
1. A method of treating a mammal for cancer, said method comprising:
treating the blood of said mammal by apheresis to remove tumor necrosis factor (TNF) receptors from the blood of said mammal and simultaneously administering to said mammal at least one agent that binds galectin-3 (Gal-3) such that the level of free unbound Gal-3 in said mammal is reduced.
2. The method of claim 1 , wherein said apheresis is conducted by withdrawing the blood of said mammal from its body, passing said withdrawn blood past an agent which binds to TNF receptors, and returning said blood, following said passage of said blood past said agent which binds TNF receptors, to the mammal's body.
3. The method of claim 2 , wherein said blood which is withdrawn from said mammal is separated into cellular components and plasma prior to passage of said plasma past said agent, and thereafter returned to said mammal.
4. The method of claim 1 , wherein said Gal-3 binder administered to said mammal is selected from the group consisting of modified citrus pectin, lactulosyl-1-leucine, antibodies specific forGal-3, modified pectins having a molecular weight of no more than 1 KD, GCS 100 and mixtures thereof.
5. The method of claim 1 , wherein said cancer is one of liver cancer, kidney cancer, breast cancer, prostate cancer, colon cancer, thyroid cancer, cancer of the gallbladder, nasopharyngeal cancer, lymphocytic leukemia, lung cancer, melanoma, multiple myeloma, glioblastoma multiforme, uterine cancer, ovarian cancer, cervical cancer, and brain cancer.
6. The method of claim 1 , wherein following said apheresis of TNF receptor said patient is treated with chemotherapy, radiation therapy or both.